These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16105919)

  • 1. A phase I trial of alfimeprase for peripheral arterial thrombolysis.
    Ouriel K; Cynamon J; Weaver FA; Dardik H; Akers D; Blebea J; Gruneiro L; Toombs CF; Wang-Clow F; Mohler M; Pena L; Wan CY; Deitcher SR
    J Vasc Interv Radiol; 2005 Aug; 16(8):1075-83. PubMed ID: 16105919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of alfimeprase in patients with acute peripheral arterial occlusion (PAO).
    Han SM; Weaver FA; Comerota AJ; Perler BA; Joing M
    J Vasc Surg; 2010 Mar; 51(3):600-9. PubMed ID: 20110153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alfimeprase.
    Drugs R D; 2008; 9(3):185-90. PubMed ID: 18457471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic.
    Shah AR; Scher L
    IDrugs; 2007 May; 10(5):329-35. PubMed ID: 17487785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound-accelerated thrombolysis in arterial and venous peripheral occlusions: fibrinogen level effects.
    Raabe RD
    J Vasc Interv Radiol; 2010 Aug; 21(8):1165-72. PubMed ID: 20656221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis.
    Toombs CF
    Haemostasis; 2001; 31(3-6):141-7. PubMed ID: 11910179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invited commentary. Efficacy and safety of alfimeprase in patients with acute peripheral arterial occlusion (PAO).
    Kashyap VS
    J Vasc Surg; 2010 Mar; 51(3):609. PubMed ID: 20206805
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
    Moll S; Kenyon P; Bertoli L; De Maio J; Homesley H; Deitcher SR
    J Clin Oncol; 2006 Jul; 24(19):3056-60. PubMed ID: 16809729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase.
    Hong TT; Huang J; Lucchesi BR
    Am J Physiol Heart Circ Physiol; 2006 Mar; 290(3):H959-67. PubMed ID: 16243915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase.
    Deitcher SR; Toombs CF
    Pathophysiol Haemost Thromb; 2005; 34(4-5):215-20. PubMed ID: 16707931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemorrhagic profile of the fibrinolytic alfimeprase after ischemia and reperfusion.
    Lu A; Kurosawa Y; Luskey K; Pyne-Geithman G; Caudell D; Clark J
    Neurol Res; 2009 Mar; 31(2):209-14. PubMed ID: 19298764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrolase: trials and tribulations.
    Markland FS; Swenson S
    Toxins (Basel); 2010 Apr; 2(4):793-808. PubMed ID: 22069611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alfimeprase for the treatment of acute peripheral arterial occlusion.
    Moise MA; Kashyap VS
    Expert Opin Biol Ther; 2008 May; 8(5):683-9. PubMed ID: 18407770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hirudin and s18886 maintain luminal patency after thrombolysis with alfimeprase.
    Lee JY; Markland FS; Lucchesi BR
    J Cardiovasc Pharmacol; 2013 Feb; 61(2):152-9. PubMed ID: 23188127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.
    Skeik N; Gits CC; Ehrenwald E; Cragg AH
    Vasc Endovascular Surg; 2013 Oct; 47(7):519-23. PubMed ID: 23899656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion.
    Heymans S; Vanderschueren S; Verhaeghe R; Stockx L; Lacroix H; Nevelsteen A; Laroche Y; Collen D
    Thromb Haemost; 2000 May; 83(5):666-71. PubMed ID: 10823259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alfimeprase: a novel recombinant direct-acting fibrinolytic.
    Deitcher SR; Funk WD; Buchanan J; Liu S; Levy MD; Toombs CF
    Expert Opin Biol Ther; 2006 Dec; 6(12):1361-9. PubMed ID: 17223743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators.
    Ouriel K; Veith FJ; Sasahara AA
    J Vasc Surg; 1996 Jan; 23(1):64-73; discussion 74-5. PubMed ID: 8558744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen Level and Bleeding Risk During Catheter-Directed Thrombolysis Using Tissue Plasminogen Activator.
    Lee K; Istl A; Dubois L; DeRose G; Forbes TL; Wiseman D; Mujoomdar A; Kribs S; Power AH
    Vasc Endovascular Surg; 2015 Oct; 49(7):175-9. PubMed ID: 26462979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.